The Role of CD123 Targeted Therapy (tagraxofusp) in the Evolving Treatment Landscape for BPDCN
An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial data. Real-world findings (Angelucci et al, ASH 2023) align with clinical outcomes, reinforcing tagraxofusp’s role in BPDCN management by supporting its safety and effectiveness in broader settings.
Video content above is prompted by the following:
- Given the efficacy/safety data from the 0114-trial evaluating tagraxofusp in BPDCN, how have you adapted your treatment approach to incorporate CD123 targeted therapy?
- Do real-world data (Angelucci et al, ASH 2023) of tagraxofusp in BPDCN complement trial data?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
